Iambic, a clinical-stage life science and technology company that uses artificial intelligence to develop medicines has raised more than $100 million in an oversubscribed financing round.
The Nov. 10 announcement followed Iambic's presentation of clinical data that showed its drug IAM1363, "demonstrated anti-tumor activity and a favorable safety profile" for cancers caused by higher-than-normal levels of the HER2 protein. The results were presented in October at the European Society for Medical Oncology Congress in Berlin, Iambic said in a statement.
